Liquid Biopsy for Disease Monitoring in Non-Small Cell Lung Cancer: The Link between Biology and the Clinic.
Adult
Aged
Alleles
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Circulating Tumor DNA
/ blood
ErbB Receptors
/ genetics
Female
Gene Frequency
High-Throughput Nucleotide Sequencing
Humans
Liquid Biopsy
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Mutation
Protein Kinase Inhibitors
/ therapeutic use
Treatment Outcome
adenocarcinoma
cell-free DNA
clinical outcomes
liquid biopsy
lung cancer
next-generation sequencing
tumour-free DNA
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
28 07 2021
28 07 2021
Historique:
received:
08
07
2021
revised:
24
07
2021
accepted:
26
07
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
12
11
2021
Statut:
epublish
Résumé
Cell-free DNA (cfDNA) analysis offers a non-invasive method to identify sensitising and resistance mutations in advanced Non-Small Cell Lung Cancer (NSCLC) patients. Next-generation sequencing (NGS) of circulating free DNA (cfDNA) is a valuable tool for mutations detection and disease's clonal monitoring. An amplicon-based targeted gene NGS panel was used to analyse 101 plasma samples of advanced non-small cell lung cancer (NSCLC) patients with known oncogenic mutations, mostly EGFR mutations, serially collected at different clinically relevant time points of the disease. The variant allelic frequency (VAF) monitoring in consecutive plasma samples demonstrated different molecular response and progression patterns. The decrease in or the clearance of the mutant alleles was associated with response and the increase in or the emergence of novel alterations with progression. At the best response, the median VAF was 0% (0.0% to 3.62%), lower than that at baseline, with a median of 0.53% (0.0% to 9.9%) ( The targeted NGS of circulating tumour DNA (ctDNA) has clinical utility to monitor treatment response in patients with advanced lung adenocarcinoma.
Identifiants
pubmed: 34440680
pii: cells10081912
doi: 10.3390/cells10081912
pmc: PMC8394732
pii:
doi:
Substances chimiques
Circulating Tumor DNA
0
Protein Kinase Inhibitors
0
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Thorac Oncol. 2014 Sep;9(9):1345-53
pubmed: 25122430
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Sci Rep. 2014 Sep 09;4:6269
pubmed: 25201768
Clin Cancer Res. 2016 May 15;22(10):2386-95
pubmed: 26747242
Lung Cancer. 2016 Aug;98:1-8
pubmed: 27393499
Oncotarget. 2018 Aug 24;9(66):32570-32579
pubmed: 30220966
Crit Rev Oncol Hematol. 2021 Jul;163:103394
pubmed: 34119656
Clin Cancer Res. 2014 Mar 15;20(6):1698-1705
pubmed: 24429876
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Cancers (Basel). 2021 May 30;13(11):
pubmed: 34070940
Ann Oncol. 2018 Apr 1;29(4):945-952
pubmed: 29346604
Clin Cancer Res. 2015 Jul 15;21(14):3196-203
pubmed: 25829397
Lung Cancer. 2019 May;131:78-85
pubmed: 31027702
Sci Rep. 2016 Feb 12;6:20913
pubmed: 26867973
Cancer Res. 2019 Mar 15;79(6):1204-1213
pubmed: 30573519
Cancer Sci. 2016 Feb;107(2):162-7
pubmed: 26577492
Cancer Res. 2001 Feb 15;61(4):1659-65
pubmed: 11245480
SLAS Technol. 2021 Feb;26(1):42-54
pubmed: 32659150
JAMA. 2014 May 21;311(19):1998-2006
pubmed: 24846037
JAMA Oncol. 2016 Mar;2(3):305-12
pubmed: 26720423
Clin Lung Cancer. 2018 Nov;19(6):518-530.e7
pubmed: 30279111
Cancer Discov. 2015 Jul;5(7):713-22
pubmed: 25934077
Oncotarget. 2016 Apr 12;7(15):20810-24
pubmed: 26989078